Skip to content
Scroll To Top
- Breast cancer remains a significant burden on human health.
- ER/PR+ (endocrine responsive) Her2- tumors occur in approximately 90,000 breast cancer patients each year, of which 20,000 develop drug resistance.
- Cancer is frequently driven by CDK4, but drug resistance is driven by CDK2.
- Drugging CDK2 has been difficult due to similarity with other essential targets, which produces too much toxicity.
- Despite advances in available drugs, the current treatments for this type of cancer do not cause durable arrest of tumors.
- This is because patients become resistant to the drug and consequently the patient's overall survival rate remains unchanged.
- We target a unique cellular pathway in order to kill—not just stop the growth of— tumor cells.
- We use the role of p27Kip1 — a key “ON-OFF” switch that modulates the activities of critical proteins involved in many cancers: CDK4, CDK6, and CDK2.
- We avoid both the problem of resistance and toxicity by targeting CDK4/6 and CDK2 with high specificity.